Sana Biotechnology (SANA) Cash from Investing Activities (2020 - 2026)
Sana Biotechnology recorded quarterly Cash from Investing Activities of $49.4 million in Q1 2026, up 399.69% quarter-over-quarter from -$16.5 million in Q4 2025, and up 197.76% year-over-year from $16.6 million in Q1 2025.
Sana Biotechnology's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $49.4 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 197.76% year-over-year to $49.4 million; the TTM figure through Mar 2026 stood at -$7.4 million (down 106.65% YoY), while the FY2025 annual figure was -$40.2 million, down 330.55% from the prior year.
- Cash from Investing Activities came in at $49.4 million for Q1 2026 at Sana Biotechnology, up from -$16.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $88.4 million in Q4 2022 to a low of -$77.2 million in Q1 2024.
- A 5-year average of $24.1 million and a median of $31.9 million in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 400.02% in 2023 and slumped 223.12% in 2024, its largest moves.
- Sana Biotechnology's Cash from Investing Activities stood at $88.4 million in 2022, then plunged by 82.69% to $15.3 million in 2023, then jumped by 207.56% to $47.1 million in 2024, then plunged by 135.03% to -$16.5 million in 2025, then surged by 399.69% to $49.4 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $49.4 million, -$16.5 million, and -$48.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - | 49.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.44 Mn |
| Mar 31, 2026 | 49.44 Mn |
| Dec 31, 2025 | -16.50 Mn |
| Dec 31, 2025 | -16.50 Mn |
| Sep 30, 2025 | -48.03 Mn |
| Sep 30, 2025 | -48.03 Mn |
| Jun 30, 2025 | 7.68 Mn |
| Jun 30, 2025 | 7.68 Mn |
| Mar 31, 2025 | 16.60 Mn |
| Mar 31, 2025 | 16.60 Mn |
| Dec 31, 2024 | 47.09 Mn |
| Dec 31, 2024 | 47.09 Mn |
| Sep 30, 2024 | 41.78 Mn |
| Sep 30, 2024 | 41.78 Mn |
| Jun 30, 2024 | 5.82 Mn |
| Jun 30, 2024 | 5.82 Mn |
| Mar 31, 2024 | -77.23 Mn |
| Mar 31, 2024 | -77.23 Mn |
| Dec 31, 2023 | 15.31 Mn |
| Dec 31, 2023 | 15.31 Mn |
| Sep 30, 2023 | 51.35 Mn |
| Sep 30, 2023 | 51.35 Mn |
| Jun 30, 2023 | 42.63 Mn |
| Jun 30, 2023 | 42.63 Mn |
| Mar 31, 2023 | 62.73 Mn |
| Mar 31, 2023 | 62.73 Mn |
| Dec 31, 2022 | 88.43 Mn |
| Dec 31, 2022 | 88.43 Mn |
| Sep 30, 2022 | 31.86 Mn |
| Sep 30, 2022 | 31.86 Mn |
| Jun 30, 2022 | 77.73 Mn |
| Jun 30, 2022 | 77.73 Mn |
| Mar 31, 2022 | 12.55 Mn |
| Mar 31, 2022 | 12.55 Mn |
| Dec 31, 2021 | -73.66 Mn |
| Dec 31, 2021 | -73.66 Mn |
| Sep 30, 2021 | -185.90 Mn |
| Sep 30, 2021 | -185.90 Mn |
| Jun 30, 2021 | -35.32 Mn |
| Jun 30, 2021 | -35.32 Mn |
| Mar 31, 2021 | 49.09 Mn |
| Mar 31, 2021 | 49.09 Mn |
| Dec 31, 2020 | 13.04 Mn |
| Dec 31, 2020 | 13.04 Mn |
| Sep 30, 2020 | -268.31 Mn |
| Sep 30, 2020 | -268.31 Mn |
| Jun 30, 2020 | -36.47 Mn |
| Jun 30, 2020 | -36.47 Mn |
| Mar 31, 2020 | 39.18 Mn |
| Mar 31, 2020 | 39.18 Mn |